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HORIMUKAI ET AL 825Background: Recent studies have suggested that epidermal
barrier dysfunction contributes to the development of atopic
dermatitis (AD) and other allergic diseases.
Objective: We performed a prospective, randomized controlled
trial to investigate whether protecting the skin barrier with a
moisturizer during the neonatal period prevents development of
AD and allergic sensitization.
Methods: An emulsion-type moisturizer was applied daily during
the first 32 weeks of life to 59 of 118 neonates at high risk for AD
(based on having a parent or sibling with AD) who were enrolled in
this study.Theonset ofAD(eczematous symptoms lasting>4weeks)
and eczema (lasting >2 weeks) was assessed by a dermatology
specialist on the basis of the modified Hanifin and Rajka criteria.
The primary outcome was the cumulative incidence of AD plus
eczema (AD/eczema) at week 32 of life. A secondary outcome,
allergic sensitization, was evaluated based on serum levels of
allergen-specific IgEdeterminedbyusingahigh-sensitivityallergen
microarray of diamond-like carbon–coated chips.
Results: Approximately 32% fewer neonates who received the
moisturizer had AD/eczema by week 32 than control subjects
(P 5 .012, log-rank test). We did not show a statistically
significant effect of emollient on allergic sensitization based on
the level of IgE antibody against egg white at 0.34 kUA/L
CAP-FEIA equivalents. However, the sensitization rate was
significantly higher in infants who had AD/eczema than in those
who did not (odds ratio, 2.86; 95% CI, 1.22-6.73).
Conclusion: Daily application of moisturizer during the first
32 weeks of life reduces the risk of AD/eczema in infants.
Allergic sensitization during this time period is associated
with the presence of eczematous skin but not with moisturizer
use. (J Allergy Clin Immunol 2014;134:824-30.)
Key words: Atopic dermatitis, atopy, allergic sensitization, food
allergy, IgE, randomized controlled trial
The prevalence of atopic dermatitis (AD) among children
continues to increase, reaching 20% in some parts of the world;
almost half of all children experience eczemawithin the first 2 years
of life. AD reduces quality of life, such as by disturbing sleep, and
should be considered a significant global burden of disease.1-4
Skin barrier dysfunction contributes to the development of AD,
and dry skin often causes inflammation of eczematous skin.
Filaggrin, a key component of the epidermal differentiation com-
plex, is required for barrier function. Disruption of the
gene encoding filaggrin (FLG) is associated with development of
AD, as well as ichthyosis. Children with mutations in FLG have
increased transepidermal water loss, even before AD develops.2,5,6
The skin stratum corneum of infants is intact shortly after birth, but
the water-sustaining barrier function of skin becomes adult like
only after the first year of life.7 Therefore it has been proposed
that intensive emollient use in early life could prevent AD, espe-
cially in infants at high risk forAD (based on having a parent or sib-
ling with AD). This hypothesis was investigated in a pilot study,8
and a large-scale randomized controlled trial (RCT) is underway
(Barrier Enhancement for Eczema Prevention trial; http://www.
beepstudy.org/).9 We initiated an RCT in 2010 to test the effects
of an emulsion-type moisturizer (2e [Douhet] emulsion; Shiseido,
Tokyo, Japan) in neonates at high risk for AD.
Several cohort studies have provided evidence that infants with
eczema tend to have other allergic diseases, such as asthma,
rhinitis, and food allergy.10,11 Moreover, topical application ofpeanut oil to neonatal skin increased the infant’s risk of peanut
allergy, indicating epicutaneous sensitization to allergens.12
Loss-of-function mutations in FLG are associated with a wide
range of allergic diseases and sensitization to airborne and food
antigens, even though filaggrin expression is limited to the skin
and oral mucosa and has not been detected in the respiratory or
intestinal mucosa.6,13-15
Primary prevention of allergic disease has been studied for
many years. However, studies of avoidance of food allergens,
aeroallergens, or both have generally produced disappointing
results.16 In this study we investigate whether daily application
of moisturizer to neonates at high risk for AD prevents
allergic sensitization, as well as development of AD. In
addition to the outcomes of this RCT, we report that the presence
of skin lesions (including AD) is a risk factor for allergic
sensitization.METHODS
Trial design and participants
We performed an investigator-blinded, randomized, controlled, parallel-
group study at the National Center for Child Health and Development
(NCCHD) in Tokyo, Japan, from November 2010 through November 2013
(Fig 1). The NCCHD is the only national hospital for mothers and children in
Japan, performing more than 1600 deliveries per year. After receiving
approval from the institutional review board (IRB) of the NCCHD in August
2010, we invited expectant mothers with family histories of AD who visited
the prenatal clinic of the NCCHD to participate in this trial. A high familial
risk of AD was defined as a history of physician-diagnosed AD for at least
1 of the unborn baby’s parents or siblings. Informed consent was
obtained from the parents before delivery. After birth, the study doctors and
a dermatology specialist confirmed the eligibility of each neonate on the basis
of the inclusion criteria (eg, absence of treatment with corticosteroids) and
exclusion criteria (eg, abnormal skin disorders, such as ichthyosis), which
had been registered with the University Hospital Medical Information
Network Clinical Trials Registry (UMIN-CTR; UMIN000004544). The
enrolled neonates were then randomly assigned to the intervention (n 5 59)
or control (n 5 59) group (Fig 2).
The intervention group began receiving daily application of an emulsion-
type emollient (2e [Douhet] emulsion) from the first week of life; petroleum
jelly was prescribed to each infant in both groups on request by the IRB.
Emollient was applied each day for 32 weeks. All infants were examined by
the same blinded dermatologist from the NCCHD at scheduled visits and at
weeks 4, 12, 24, and 32 of life. At each visit, the dermatologist examined the
skin condition of the infant and recorded a diagnosis of AD, eczema, skin rash
without pruritus, or healthy skin without any lesions. Theworldwide and most
validated criteria for diagnosis did not specify a time frame for AD
development, describing a chronic or relapsing course,17-19 and therefore it
was not possible to diagnose an infant’s AD immediately after his or her
pruritic skin lesion emerged.
FIG 2. Study flow chart.
FIG 1. Study design.
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case, setting the time for AD development to at least 2 weeks. The same
authors proposed setting the time frame as at least 4 weeks.20We incorporated
these criteria for an incident case of AD according to our definition of infantile
eczema and AD. In our trial AD was defined as ‘‘itchy eczema at typical loca-
tions that lasted for at least 4 weeks,’’ and infantile eczema was defined as the
same eczema that lasted at least 2 weeks. Then these criteria were registered.
Because AD and infantile eczema, as defined above, were essentially synon-
ymous, we combined them as AD/eczema for this study. If an infant with skin
rash or eczematous skin did not show any sign of pruritus, the dermatologist
made a diagnosis of skin rash. When given a diagnosis of AD/eczema, infants
were immediately removed from the study and treated appropriately. We in-
structed the parents to visit our outpatient clinic if their infants had any skin
problems (Fig 1).
Outcomes
We registered this trial design, including the hypothesis and outcome
measures, at UMIN-CTR (UMIN000004544). We proposed that protection of
the skin barrier with a moisturizer beginning in the neonatal period would be a
safe and effective strategy for prevention of AD and allergic sensitization. The
primary outcome measure was the cumulative rate of incidence of AD,
eczema, or both by temporal observation. The diagnostic criteria for infantile
eczema, AD, or both (AD/eczema) were developed based on a modification of
the United Kingdom Working Party’s criteria and were applied by a
dermatology specialist, as described above. Briefly, those criteria were a
pruritic skin condition of at least 2 weeks’ duration, visible flexural dermatitis
(and/or on the cheeks and extensor surfaces), a history of dry skin, and a family
history in a first-degree relative of the enrolled neonate.
Secondary outcome measures were the presence of allergen-specific IgE,
transepidermal water loss (to measure stratum corneum hydration and pH at
birth [baseline] and at weeks 4, 12, 24 and 32 of life; Vapo Meter, SW-4002;
Delfin Technologies, Kuopio, Finland), stratum corneum hydration (Moisture
Meter, SC-5; Delfin Technologies), stratum corneumpH (epidermal; Skin-pH-
Meter, PH905; Courage & Khazaka Electronic GmbH, Koln, Germany), and
skin colonization by Staphylococcus aureus (measured at the cheek).
Onset of allergic diseases, such as food allergy (registered onNovember 10,
2010), and onset of asthma were added as outcome measures on April 12,
2011, in response to a recommendation by the evaluation committee of the
Ministry of Health, Labour and Welfare. Skin barrier functions were assessed
by using the previously described methods.21Statistical analyses
Analyses of the primary and secondary outcomes were conducted
according to the intent-to-treat principle and based on the full analysis set,
which included all randomized subjects. For an analysis of allergic
sensitization, subjects without serum specific IgE (detected by using the
diamond-like carbon [DLC] chip with high-density allergen immobilization
and high sensitivity22 at week 32; n5 2 for the intervention group and n5 5
for the control group) were excluded.
The primary outcome (cumulative rate of incidence of AD, eczema, or both
by temporal observation) was analyzed by using the log-rank test. Thesignificance level was set at .05. The Kaplan-Meier method was used to
estimate the cumulative incidence of AD/eczema for each group, and the Cox
regressionmodel was applied to estimate the hazard ratio between groups. The
Mann-Whitney U test and x2 test with the Yates correction were used with
continuous and categorical variables, respectively, to analyze secondary
outcomes. Demographic and baseline data are presented as means, SDs, and
proportions, as appropriate.
Once the data were collected from all subjects, we conducted several post
hoc analyses. To evaluate the association between sensitization to foods and
AD, we constructed a contingency table that dichotomized serum levels of
antigen-specific IgE (based on results from the DLC assay) measured at
week 32 at several cutoff values. The odds ratio (OR) and 95% CI were
used to evaluate the degree of association. Statistical analyses were conducted
with SPSS 17.0 software for Windows (SPSS, Chicago, Ill) and R software
(version 3.0.1, http://www.R-project.org).Consolidated Standards of Reporting Trials topics
Methods relating to Consolidated Standards of Reporting Trials statement
(http://www.consort-statement.org/) and other methods are described in the
Methods section in this article’s Online Repository at www.jacionline.org.
RESULTS
Characteristics of neonates
We invited 183 expectant mothers from families at high risk for
AD to participate in the study; 118 neonates were enrolled and
randomly assigned to 2 groups of 59 infants each (Fig 2). Two
infants assigned to the control group were found to have
accidently received and used the emollient after opening the
blinded data; 1 withdrew consent, and another completed the
study without skin lesions. All 118 neonates were included as
the intent-to-treat population (Table I) and the 2 infants who
mistakenly received the intervention were classified into the con-
trol group. During the trial, 8 families withdrew informed consent
(2 infants in the intervention group and 6 infants in the control
group). The dermatologist withdrew an infant in the intervention
group from the study because she or he had a hemangioma. After
the second scheduled examination, we found that the incidence of
AD was significantly lower in the intervention group than in the
control group and reported this observation to the IRB of the
NCCHD. The trial was discontinued at the recommendation of
the NCCHD’s IRB on November 30, 2013; by this time, 10
neonates had left the study (6 in the intervention group and 4 in
the control group).
TABLE I. Baseline characteristics of the study population
Characteristic
Intervention group
(n 5 59)
Control group
(n 5 59)
Infant girl, no. (%) 26/59 (44.1) 24/59 (40.7)
Birth
Mean ages of mothers at
delivery (y)
35.8 6 4.80 35.0 6 4.85
Cesarean section, no. (%) 16/59 (27.1) 13/59 (22.0)
Mean gestational age (wk) 39.1 6 0.97 39.0 6 1.07
Mean birth weight (g) 3074 6 363 3034 6 366
Breast-feeding at 1 mo (%) 29/58 (50.0) 28/58 (48.3)
Family history
Food allergy (%) 24/59 (40.7) 21/59 (36.8)
Bronchial asthma (%) 24/59 (40.7) 21/59 (36.8)
Allergic rhinitis (%) 46/59 (78.0) 48/59 (84.2)
Mean no. of siblings 0.34 6 0.58 0.38 6 0.62
Environmental exposures
Smoking in the family, no. (%) 10/59 (16.9) 7/57 (12.3)
Any pet, no. (%) 12/58 (21.4) 13/57 (23.2)
Dog, no. (%) 8/58 (13.8) 6/57 (10.5)
Cat, no. (%) 2/58 (3.4) 4/57 (7.0)
Skin barrier function
TEWL
Mean lower leg 8.31 6 2.67 8.40 6 2.92
Mean forehead 8.29 6 4.77 7.62 6 3.15
Stratum corneum hydration
Mean lower leg 13.7 6 5.93 13.5 6 5.94
Mean forehead 20.6 6 10.7 19.2 6 11.6
Mean pH 5.65 6 0.59 5.61 6 0.39
TEWL, Transepidermal water loss.
FIG 3. Proportions of infants who did not have AD/eczema. Kaplan-Meier
plots show the proportions of infants in the intervention (circle) and control
(triangle) groups with AD/eczema during the first 32 weeks of life.
The log-rank test indicated statistically significant differences between
groups (P 5 .012).
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 4
HORIMUKAI ET AL 827Among 118 infants evaluated, 47 had AD/eczema (19/59 in the
intervention group and 28/59 in the control group), 13 had skin
rash without pruritus (6 in the intervention group and 7 in the
control group), and 31 did not have any skin lesions (20 in the
intervention group and 11 in the control group). There were 5
infants (2 in the intervention group and 3 in the control group)
who used moisturizers for skin disorders other than AD/eczema.
The dermatology specialist stopped giving the emollient to 3
infants whose skin lesions seemed to be the result of urticaria or
contact dermatitis caused by emulsion-type emollients (related
adverse events). After several days, however, the doctor judged
that these skin lesions were not adverse events because they
disappeared rapidly and similar lesions were not seen when the
same emollients were used again. These 3 infants did not have
AD/eczema or skin rash when they were followed for 32 weeks.
Among 8 families who withdrew consent, 2 families in the
intervention group said that it was difficult for them to visit the
NCCHD. There were no infants from families that withdrew
consent who had skin lesions. In summary, adverse events caused
by this emulsion-type emollient were not observed during this
RCT.
Because the IRB recommended permitting application of
petroleum jelly when the parents thought it necessary, we
calculated the amount of these 2 types of moisturizers used by
each group based on their diaries. The mean daily amount of
emulsion-type moisturizer used by the intervention group was
7.86 6 4.34 g (0 g for the control group, excluding the 2 infants
placed in the wrong group). The mean daily amount of petroleum
jelly applied to the control group was 0.101 6 0.286 g (mean
frequency of use, 0.235 d/wk). Petroleum jelly (20 g per bottle)
was prescribed to all neonates born at the NCCHD, but we had noinformation about how much was used by the intervention group.
Nevertheless, only a few of the parents occasionally used a small,
almost ignorable, amount of the jelly on their infants.Primary and secondary outcomes
During their first 32 weeks of life, 19 infants in the intervention
group had AD/eczema compared with 28 infants in the control
group. Calculation of cumulative incidence values for AD/
eczema by using the Kaplan-Meier method showed that the
intervention group maintained intact skin for a significantly
longer period than the control group (P 5 .012, log-rank test;
Fig 3). Cox regression analysis showed the risk of AD/eczema
to be significantly lower in the intervention group (hazard ratio,
0.48; 95% CI, 0.27-0.86).
In analyses of secondary outcomes (levels of allergen-specific
IgE), we evaluated the serum levels of anti–egg white and
anti-ovomucoid IgE in infants at 32 weeks,22 as described in
the Methods section of this article’s Online Repository. IgE
antibody data were converted to CAP-FEIA data after confirming
the correlation between the data sets (see Fig E1 in this article’s
Online Repository at www.jacionline.org). However, we were
not able to demonstrate a statistically significant effect of
emollient on the rate of allergic sensitization based on level of
IgE antibody against egg white (0.34 kUA/L CAP-FEIA equiva-
lents); the proportions of infants who were sensitized by allergen
were similar in the intervention and control groups (Table II18 and
see Fig E2 in this article’s Online Repository at www.jacionline.
org).
The intervention group had significantly higher levels of
stratum corneum hydration in the lower leg at weeks 12 and 24
compared with those seen in the control group (see Fig E3 in this
article’s Online Repository at www.jacionline.org). In both
groups 6.1% of infants (7/115 cases measured) had positive test
results for S aureus in cheek samples at birth, and 22.4% had pos-
itive test results (19/85 cases measured) at week 12. There was no
significant difference between percentages of infants with
positive test results for S aureus in the intervention (26.0%
TABLE II. Allergic sensitization at week 32
Level of specific IgE
Intervention
group (n 5 48)
Control
group (n 5 44) P valuey
Egg white (kUA/L*)
>_0.35 42% (20/48) 45% (20/44) .88
>_0.70 38% (18/48) 45% (20/44) .57
Ovomucoid (kUA/L*)
>_0.35 19% (9/48) 6.8% (3/44) .17
>_0.70 13% (6/48) 4.5% (2/44) .33
*We converted the levels of specific IgE (binding unit of IgE [BUe]/mL) measured
with a DLC chip into CAP-FEIA equivalents (kUA/L) based on a previously described
method.22 Cutoff values for allergic sensitization were set at 0.35 or greater or 0.7 or
greater.
The x2 test was used to calculate the difference between the 2 study groups.
TABLE III. Numbers of Infants with AD/eczema and allergic
sensitization at week 32
Level of specific IgE
With AD/eczema
(n 5 43)
Without AD/eczema
(n 5 49)
P
valuey
Egg white (kUA/L*)
>_0.35 56% (24/43) 33% (16/49) .043
>_0.70 56% (24/43) 29% (14/49) .015
Ovomucoid (kUA/L*)
>_0.35 19% (8/43) 8.2% (4/49) .24
>_0.70 12% (5/43) 6.1% (3/49) .57
*We converted the levels of specific IgE (binding unit of IgE [BUe]/mL) measured
with a DLC chip into CAP-FEIA equivalents (kUA/L) based on a previously described
method.22 Cutoff values for allergic sensitization were set at 0.35 or greater or 0.7 or
greater.
The x2 test was used to calculate the difference between the 2 study groups.
TABLE IV. Allergic sensitization based on cutoff levels of IgE
specific for egg white at week 32
Cutoff values for
specific IgE for egg
white
Skin lesion (1) vs
others, OR (95% CI)
AD/eczema (1) vs
others, OR (95% CI)
DLC chip
(BUe/mL)
CAP-FEIA
(kUA/L)*
54.0 0.10 3.01 (1.27-7.16) 2.34 (1.001-5.48)
67.4 0.13 3.38 (1.41-8.07) 2.54 (1.09-5.95)
72.9 0.14 3.79 (1.58-9.14) 2.76 (1.18-6.48)
82.7 0.16 3.49 (1.46-8.39) 3.00 (1.28-7.06)
92.3 0.17 3.23 (1.35-7.71) 3.27 (1.39-7.72)
124.3 0.23 2.99 (1.26-7.11) 2.95 (1.26-6.90)
126.1 0.23 2.77 (1.17-6.57) 2.66 (1.15-6.20)
151.6 0.28 2.57 (1.08-6.08) 2.41 (1.04-5.59)
167.8 0.31 2.90 (1.21-6.93) 2.63 (1.13-6.12)
170.6 0.32 3.29 (1.36-7.97) 2.88 (1.23-6.72)
170.8 0.32 3.05 (1.26-7.39) 2.61 (1.12-6.08)
173.2 0.32 2.84 (1.17-6.85) 2.38 (1.02-5.52)
182.2 0.34 3.24 (1.32-7.96) 2.61 (1.12-6.08)
361.7 0.66 3.73 (1.49-9.36) 2.86 (1.22-6.73)
364.4 0.67 4.35 (1.69-11.2) 3.16 (1.33-7.49)
412.5 1.21 4.04 (1.57-10.4) 2.88 (1.21-6.81)
474.8 2.18 3.76 (1.46-9.67) 2.62 (1.11-6.20)
540.3 3.20 3.50 (1.36-8.99) 2.90 (1.21-6.94)
607.0 3.93 4.13 (1.55-11.0) 3.23 (1.33-7.82)
754.2 5.28 3.84 (1.44-10.2) 2.94 (1.22-7.12)
801.1 5.71 3.57 (1.34-9.51) 2.68 (1.11-6.50)
824.6 5.92 4.31 (1.55-12.0) 3.00 (1.22-7.39)
843.4 6.09 4.00 (1.44-11.1) 3.39 (1.35-8.49)
1004.2 7.56 3.71 (1.33-10.4) 3.09 (1.23-7.74)
1049.7 7.98 3.44 (1.23-9.62) 2.81 (1.12-7.06)
BUe, Binding unit of IgE.
*The levels of specific IgE (BUe/mL) measured with a DLC chip were converted into
CAP-FEIA equivalents (kUA/L) by using a previously described method.
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(x2 analysis).
Post hoc analysis
Recent epidemiologic studies raised the possibility of epicuta-
neous sensitization to food allergens,23 whereas others reported
that some allergic diseases can be treated by repeated epicutane-
ous exposure to allergens.24 Therefore we proposed the hypothe-
sis that allergic sensitization can occur through eczematous but
not healthy skin.23 In a post hoc analysis of our data, we compared
allergic sensitization in infants with and without AD/eczema at 32
weeks. We found that a greater proportion of infants with AD/
eczema had allergic sensitization based on the serum levels of
anti–egg white IgE (cutoff level of 0.34 kUA/L CAP-FEIA
equivalents) than infants without AD/eczema (P 5 .043,
Table III).18 The OR for allergic sensitization in infants with
AD/eczema was 2.86 (95% CI, 22-6.73; Table IV22 and see Fig
E4 in this article’s Online Repository at www.jacionline.org).
Thirteen infants of a total population had skin rash without
pruritus. Six of these 13 infants also had allergic sensitization, and
therefore we investigated whether there was an association
between allergic sensitization and the presence or absence of
skin lesions. The OR for allergic sensitivity (cutoff level of 0.34
kUA/L CAP-FEIA equivalents) in infants with skin lesions
compared with that in infants without skin lesions was 3.73
(95% CI, 1.49-9.36; Table IV and see Fig E4, B in this article’s
Online Repository at www.jacionline.org).
We have shown in this and previous studies that measurements
of IgE by using a DLC chip correlate with those determined by
using CAP-FEIA (see Fig E1). To prove the accuracy ofCAP-FEIA equivalents measured by using a DLC chip in allergic
sensitization, we calculatedORs for allergic sensitization using 25
different cutoff levels, ranging from 0.1 to 8.0 kUA/L (Table IV).
We found that ORs for allergic sensitization were greater for
infants with AD/eczema than those without AD/eczema and for
infants with compared with those without skin lesions when
cutoff values were set at 25 different levels.
We detected loss-of-function mutations in FLG in 6 of the 57
DNA samples from infants. We were not able to demonstrate
whether development of AD/eczema correlates with the presence
of mutations, probably because of the small sample size (data not
shown).DISCUSSION
In a prospective RCTwe investigated whether protection of the
skin barrier with an emollient during the first 32 weeks of life
prevents AD/eczema development in infants. A previous
uncontrolled pilot study investigated whether a moisturizer can
prevent AD,8 but to our knowledge, this is the first RCT to
investigate this question.
This trial was performed at only the NCCHD, mainly because
of its logistic support. We tested the effects of an emulsion-type
moisturizer (2e [Douhet] emulsion) because it is widely used,
including for infants, and its composition has been disclosed.
Studies to investigate the effects of other moisturizers on other
populations are needed to support our findings.
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Worldwide andmost validated criteria for the diagnosis of AD did
not define the time frame of signs and symptoms,17-19 resulting in
its inability in diagnosis for early onset of AD in infancy. For this
trial, we made the diagnosis of AD/eczema based on modified
criteria proposed by Simpson et al.8,20
Intensive use of a moisturizer was reported to increase
hydration of the stratum corneum in neonatal skin25; we
confirmed this observation in our study. Daily application of an
emulsion-type moisturizer during the first weeks of life increased
stratum corneum hydration at week 12 compared with that seen in
infants who occasionally received the minimum amount of
petroleum jelly (control subjects). We found no statistically
significant differences between the intervention and control
groups in detection of S aureus in cheek samples or FLG
mutations. This lack of association could be a result of insufficient
statistical power, and therefore further studies are needed.
Primary prevention of allergic sensitization
Several cohort studies revealed that early-onset eczema
increases the risk for allergic diseases, such as asthma, allergic
rhinitis, and food allergy.10,11 The presence of AD was the main
skin-related risk factor for food allergen sensitization in young
infants.26 We confirmed that levels of anti–egg white and
anti-ovomucoid IgEs measured by using a DLC chip correlate
with those from CAP-FEIA. IgE-mediated egg allergy is one of
the most common forms of food allergy; IgE against egg white
is often used as a marker of atopy in infants.27,28 In our study
we were not able to show the significant effect of emollient on
the prevention of allergic sensitization based on the level of IgE
antibody against egg white; similar proportions of infants were
sensitized in the intervention and control groups. However, we
showed that a higher proportion of infants with AD/eczema had
allergic sensitization based on serum concentrations of anti–egg
white IgE compared with infants without AD/eczema. Further-
more, we found infants with skin lesions to have a more than
3-fold greater risk for allergic sensitization than infants without
skin lesions based on 20 of 25 different cutoff points (range,
0.1-8.0 kUA/L CAP-FEIA equivalents). Collectively, these
findings indicate that the presence of eczematous skin, rather
than a lack of emollient use, induces or promotes sensitization
to allergens, such as egg white, during the first 8 months of life.
The mechanisms of this process are unclear. Levels of tight
junction proteins (eg, claudin-1) between epidermal cells are
significantly decreased in patients with AD compared with those
seen in nonatopic subjects.29 Also, Langerhans cells were
reported to elongate their dendrites, penetrate keratinocyte tight
junctions, and take up antigens when the Langerhans cells were
activated by means of tape stripping.30 These results could
provide information on how eczematous skin promotes allergen
sensitization.Future directions
Findings from our RCT support our hypothesis that daily
application of a moisturizer would prevent development of
AD/eczema during the first 32 weeks of life. Contrary to our
hypothesis, however, allergic sensitization, as assessed on the
basis of acquisition of anti–egg white IgE, was not affected by
application of the emollient. Our post hoc analysis revealed that
the incidence of allergic sensitization was significantly increasedamong infants with skin lesions, including those caused by
AD/eczema, compared with that seen in infants without these
lesions. However, studies of a larger number of subjects might
find that moisturizer use reduces allergic sensitization by
preventing development of AD/eczema. In this post hoc analysis
skin rash that did not fulfill the present criteria for AD/eczema,
such as a lack of pruritus, was proposed to contribute to allergen
sensitization. Allergic sensitization sometimes precedes and
predicts the development of eczema,31 and we have described
the presence of low-affinity IgE against food antigens in blood
and cord blood samples from newborns.32 Therefore further
studies should examine whether sensitization might occur
through the placenta or neonatal gastrointestinal tract. It will
be interesting to examine the temporal sequence of allergic
sensitization, especially of epicutaneous sensitization to food
antigens, by separately measuring levels of low-affinity and
ordinary IgEs against food antigens.
We thank Professor Emiko Noguchi for providing information regarding
the primer design for FLG mutations. We also thank Ms Kazuko Hayase and
Ms Akiko Maruta of the NCCHD for their excellent assistance.
Clinical implications: Daily application of emollient reduces the
risk of AD/eczema by 32 weeks. We might be able to reduce the
prevalence of allergic sensitization by preventing the develop-
ment of AD/eczema.
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Interventions, randomization, and blinding
The research pediatricians (K.H. andK.M.) at the Division of Allergy of the
NCCHD enrolled participants who met our criteria. Randomization of
neonates into 2 groups was performed by means of random permuted blocks
of size 4 at the Clinical Research Center of the NCCHD. The effect of
intervention was evaluated as the cumulative incidence of AD/eczema, as
registered at the UMIN-CTR. Dermatologists in the Division of Dermatology
of the NCCHD examined the infants at scheduled visits in an investigator-
blinded manner. The list of randomization was kept at the Clinical Research
Center of the NCCHDuntil the end of the study tomaintain the blinded state of
the investigators.
The emollient used was an emulsion-type moisturizer, 2e emulsion, which
was purchased from Shiseido. It was selected because it is commercially
available and in widespread use in Japan, including for patients with AD and
infants, and its composition has been disclosed. It contains glycerin, xylitol,
butylene glycol, behenyl alcohol, batyl alcohol, hydrogenated polydecene,
dimethicone, squalane, pentaerythrityl tetraethylhexanoate, Simmondsia
chinesis (JOJOBA) seed oil, PEG-60 glyceryl isostearate, PEG-5 glyceryl
isostearate, carbomer, potassium hydroxide, sodium metaphosphate, phenox-
yethanol, tocopherol, and water (see also http://2e.shiseido.co.jp/products/
emulsion.html) but not preservatives or mineral oils. The moisturizer was
applied at least once daily to the whole body surface of infants in the
intervention group. The participating families in both groups were routinely
given a 20-g bottle of petroleum jelly at birth. As recommended by the IRB,
we permitted all the families to use the petroleum jelly when they believed
it necessary. They recorded the amounts of emulsion-type moisturizer and
petroleum used each day. The families also kept a daily diary regarding their
infants’ skin condition (rash, erythema, itch, or scratch) and the areas to which
the moisturizers were applied. We instructed the parents/caregivers to use
commercially available soap with mild cleansing potency for their baby’s
bathing. Parents were instructed to bath their babies at least once a day. These
instructions were just based on local customs. Blood samples (200 mL) were
collected from each infant at weeks 1 (birth), 12, and 32. Swab samples to
determine skin colonization were collected at weeks 1, 4, 12, and 32. Physical
condition and skin barrier functions, such as the stratum corneum water
concentration, were also evaluated at weeks 1, 4, 12, and 32.
Sample size
The sample size was calculated based on the preliminary results of our
unpublished cohort study at the NCCHD. In that study infants at 6 to 8 months
of age had a 47% cumulative prevalence of eczema, which was based on a
modification of the questionnaire described in the International Study of
Asthma and Allergies in Childhood report.E1 Our experience shows that the
rate of eczema assessed by using the modified International Study of Asthma
and Allergies in Childhood questionnaire is always considerably higher than
actual diagnoses by dermatologists; on the other hand, our invited participants
(families) had a high risk of AD. Because we have no other verification tools
for estimation, we estimated that 47% of infants who received a moisturizer in
this study and 20% of infants who did not receive a moisturizer would have
eczema, with 80% power at the 5% significance level and assuming a dropout
rate of 5%. It was estimated that 37 cases were needed in each group.We noted
that the rate of eczema is fairly high among infants born in the NCCHD
compared with those born in other regions in Japan, although the reason is
unclear. One might speculate that a high socioeconomic status could affect
the rate because the average income of expectant parents at the NCCHD
was estimated to be twice that of expectant parents in other regions.E2 In
addition, the IRB of the NCCHD did not allow us to use ‘‘participants who
do not use emollients’’; we gave petroleum jelly to all the participating parents
so that they could apply it when they thought their baby’s skin was very dry.
Thus we adopted an adaptive study design; that is, we decided to re-estimate
the sample size based on the results of interim analyses. The IRB of the
NCCHD approved our study design in August 2010. In November 2012, based
on the scheduled plan, we had performed the first interim analysis when half of
the estimated participants reached the end point. The sample size of each
groupwas calculated as 108 cases based on the first interim analysis. However,4 control group participants had withdrawn informed consent, whereas only
1 intervention group participant had done so. As a result, we decided to
emphasize the importance of the control group to the RCT when explaining
the study to potential participants.
The second interim analysis was performed in November 2013, as had been
scheduled. We enrolled a total of 118 neonates (59 in each group) and found
that the incidence of ADwas significantly lower in the intervention group than
in the control group.We reported this to the IRBof theNCCHDaccording to its
due process.We decided to discontinue the study at the recommendation of the
IRBof theNCCHDonNovember 30, 2013, at which time 10 neonates (6 in the
intervention group and 4 in the control group) were continuing in the study.
Methods to measure allergen-specific IgE
antibodies
As secondaryoutcomemeasures registered at theUMIN-CTR, serum levels of
several allergen-specific IgE antibodies weremeasured by using a novel allergen
microarray on a DLC-coated chip, a high-sensitivity detection method for
allergen-specific antibodies, as previously described.E3 We used mainly a DLC
chip method to measure allergen-specific IgE antibodies because it requires
less than 2 to 5 mL of blood, although we sometimes measured the same
allergen-specific IgE antibodies using the ImmunoCAP solid-phase IgE assay
(CAP-FEIA; Thermo Scientific, Uppsala, Sweden) when the blood sample vol-
ume was sufficient. The DLC chip, but not CAP-FEIA, can detect low-affinity
IgE antibodies that are present in fetuses and neonates.E4 IgE antibody levels
measured with a DLC chip correlate well with those determined by using
CAP-FEIAwhen adult samples are used, and we confirmed this correlation by
using our own neonatal samples when we had a sufficient blood volume to test.
We successfully measured 3 allergen-specific IgE antibodies (to egg white, ovo-
mucoid, and milk) using both a DLC chip and CAP-FEIAmethods (Fig E1). For
anti-milk antibody, correlation between the values obtained by using the 2
methods was not sufficiently high, suggesting the presence of low-affinity IgE
antibodies. As a consequence, levels of anti–egg white and anti-ovomucoid
IgE antibodies measured with a DLC chip correlated significantly with those
determined by using CAP-FEIA and were used in further analyses. We were
not able to validate the correlation between IgE antibodies detected with the
DLC chip and those detected with CAP-FEIA in our samples at 1 and 12 weeks.
FLG mutation analysis
The representative FLG mutation sites found in the Japanese population
were detected by using the primer sets described below. The p.R501*,
p.S2889*, and p.S3296* mutations were screened by using TaqMan analysis
(Life Technologies, Thermo Fisher Scientific, Waltham, Mass), as described
previously.E5,E6 The following mutations were screened for by using TaqMan
analysis with newly developed primers and probes. The c.3321delA mutation
was screened with 2 primers (59-TGATAGTGAGGGACATTCAGAGGA-39
and 59-TTCATGAGTGCTCACCTGGTAGAT-39) and 2 probes (59-VIC-
ACCTCCCCCTGACCAG-MGB-39 and 59-FAM-ACCTCCCCCGACCAG-
MGB-39). The p.Q1701* mutation was screened with 2 primers (59-AGCA
GACAGCTCCACAGACT-39 and 59-CTGTGTGTCTGACTCTTCTGAG-
39) and 2 probes (59-VIC-CAGACAAGATTCATCTGT-MGB-39 and 59-FAM-
GCAGATAAGATTCATCTGT-MGB-39). The p.S2554* mutation was
screened with 2 primers (59-GCAAGCAGACAAACTCGTAACGAT-39 and
59-CTGGCTAAAACTGGATCCCCA-39) and 2 probes (59-VIC-CCAGGGA
CAATCAGA-MGB-39 and 59-FAM-CCAGGGACAATGAGA-MGB-39).
The p.K4022* mutation was screened by using TaqMan analysis with 2
newly developed probes (59-VIC-CGTTTGGTAAAGATCATC-MGB-39 and
59-FAM-CGTTTGGTTAAGATCAT-MGB-39) and 2 primers (59-TGTT
TTCAAGGAAAGATCTGATATCTG-39 and 59-ATATATCACTAGAATG
GCCACATAAACC-39).
Bacterial culture of Staphylococcus aureus
Bacteria on the swabs obtained from the cheeks of infants were inoculated
onto No. 110 Staphylococcus species–selective agar plates (Nissui
Pharmaceutical, Tokyo, Japan) and cultured. Each bacterial colony was
examined regarding the expression of femA and femB genes to confirm the
presence of S aureus.
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FIG E1. Correlation of allergen-specific IgE values determined by using a DLC chip system and CAP-FEIA.
The values of anti-egg white (A), anti-ovomucoid (B), and anti-milk (C) IgE antibodies derived from 72, 48,
and 29 infants, respectively, could be determined by using both the CAP-FEIA and DLC chip methods, and
the correlations between these values obtained from the same samples were tested by means of linear
regression analysis. BUe, Binding unit of IgE.
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FIG E2. Allergic sensitization at weeks 12 and 32: comparison between the intervention and control groups.
The serum levels of egg white–specific IgE (binding unit of IgE [BUe]/mL) in infants at weeks 12 and 32 were
measured with a DLC chip and converted into CAP-FEIA equivalents (kUA/L) by using a previously described
method.E3 Note that high correlation between these 2 data sets with the present samples was confirmed
only at week 32. The values obtained from AD/eczema-positive infants are shown in warm colors, and those
from AD/eczema-negative infants are shown in cold colors.
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A B
FIG E3. Stratum corneum hydration (SCH) change in the lower leg (A) and forehead (B) in each group. SCH
values (relative impedance) on the outside of the lower leg (Fig E3, A) and forehead (Fig E3, B) were shown
at baseline (week 0) and at 4, 12, 24, and 32 weeks of age. Symbols (circles and triangles) and bars stand for
means and SDs. SCH values were significantly higher for the lower leg in the intervention group at 12 weeks
of age compared with those in the control group (P < .05, ANOVA).
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FIG E4. Allergic sensitization at weeks 12 and 32. Serum levels of egg white–specific IgE (binding unit of IgE
[BUe]/mL) in infants at weeks 12 and 32 were measured with a DLC chip and converted into CAP-FEIA
equivalents (kUA/L). A, The AD/eczema-positive group had a higher proportion of infants sensitized with
egg white at 0.35 kUA/L CAP-FEIA equivalents at week 32 compared with the other group (P 5 .043).
B, The skin lesion–positive group had a higher proportion of infants sensitized with egg white at 0.70
kUA/L CAP-FEIA equivalent at week 12 (P 5 .0059) and week 32 (P 5 .0017) compared with the other group.
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